Background/Aims This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.
Results The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.
Citations
Citations to this article as recorded by
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma Lili Meng, Zhenjian Jiang, Guangyue Shen, Shulan Lin, Feng Gao, Xinxin Guo, Bin Lv, Shuying Hu, Zheng Ni, Shanghua Chen, Yuan Ji European Journal of Cancer Prevention.2025; 34(5): 456. CrossRef
Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee American Journal of Transplantation.2025; 25(6): 1285. CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Optimizing patient selection and immunosuppression in improving long-term survival after living donor liver transplantation for hepatocellular carcinoma JaRyung Han, Young Seok Han Annals of Liver Transplantation.2025; 5(1): 1. CrossRef
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang Clinical Transplantation.2025;[Epub] CrossRef
Toward optimized immunosuppression balance in liver transplantation: Clinical insights from lower tacrolimus exposure Sung-Min Kim Annals of Liver Transplantation.2025; 5(2): 65. CrossRef
High Number of Plasma Exchanges Increases the Risk of Bacterial Infection in ABO-incompatible Living Donor Liver Transplantation Mun Chae Choi, Eun-Ki Min, Seung Hyuk Yim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim Transplantation.2024; 108(8): 1760. CrossRef
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo Hepatology International.2024; 18(2): 299. CrossRef
Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto Cancers.2024; 16(7): 1243. CrossRef
Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez Biomedicines.2024; 12(6): 1302. CrossRef
Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options Filippo Pelizzaro, Alberto Ferrarese, Martina Gambato, Alberto Zanetto, Francesco Paolo Russo, Giacomo Germani, Marco Senzolo, Mario Domenico Rizzato, Caterina Soldà, Alessandro Vitale, Enrico Gringeri, Umberto Cillo, Patrizia Burra Hepatoma Research.2024;[Epub] CrossRef
Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience Peng Liu, Xin Wang, Huan Liu, Shu-Xian Wang, Qing-Guo Xu, Lin Wang, Xiao Xu, Jin-Zhen Cai Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 34. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study Sami Akbulut, Murat Tamer, Serdar Saritas, Ozlem Unal, Musap Akyuz, Selver Unsal, Zeynep Kucukakcali, Ertugrul Karabulut, Sertac Usta, Sezai Yilmaz Transplantation Proceedings.2023; 55(5): 1231. CrossRef
Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee International Journal of Infectious Diseases.2023; 131: 166. CrossRef
Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat Hao Wang, Ruining Yang, Zhenglu Wang, Lei Cao, Dejun Kong, Qian Sun, Sei Yoshida, Jiashu Ren, Tao Chen, Jinliang Duan, Jianing Lu, Zhongyang Shen, Hong Zheng International Immunopharmacology.2023; 124: 110810. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee Journal of Clinical Medicine.2022; 11(10): 2806. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim Scientific Reports.2022;[Epub] CrossRef
The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report Incheon Kang, Jae-myeong Lee, Jae Geun Lee Korean Journal of Transplantation.2022; 36(4): 294. CrossRef
Can hepatocellular carcinoma recurrence be prevented after liver transplantation? Jong Man Kim Clinical and Molecular Hepatology.2021; 27(4): 562. CrossRef
Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients Po-Jung Hsu, Hao-Chien Hung, Jin-Chiao Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee, Chen-Fang Lee Current Oncology.2021; 28(6): 4281. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo Cancers.2021; 13(19): 4882. CrossRef
First
Prev
